Andere Sprachen Kiromic BioPharma, Inc.

Aktien

A3D7BN

US4976342042

KRBP

Markt geschlossen - OTC Markets Andere Börsenplätze 21:47:36 15.05.2024			% 5 Tage	% 1. Jan.
2,76 ^USD	+3,37 %		+8,24 %	+217,24 %

10.05.	Kiromic BioPharma, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
24.04.	Kiromic BioPharma, Inc. meldet gleichbleibend günstige Sicherheit, Verträglichkeit und Wirksamkeit bei den ersten drei Patienten der klinischen Studie mit Deltacel-01	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10.05.
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	01.05.
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	24.04.
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients	24.04.
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	02.04.
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial	02.04.
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	02.04.
EARLY EFFICACY RESULTS SHOW PRIMARY LUNG TUMOR STABILIZATION AND COMPLETE DISAPPEARANCE OF BRAIN METASTASES IN SECOND PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL	20.03.
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial	19.03.
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial	19.03.
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Kiromic BioPharma : Corporate Presentation	06.03.
KIROMIC BIOPHARMA ADDS VIRGINIA ONCOLOGY ASSOCIATES, PC AS THE SECOND CLINICAL TRIAL SITE IN THE ONGOING PHASE 1 DELTACEL-01 TRIAL	04.03.
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial	01.03.
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th	29.02.
Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th	28.02.
RESULTS FROM FIRST PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL INDICATE TUMOR REDUCTION AT TWO MONTHS	15.02.
Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	14.02.
Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months	14.02.
Kiromic BioPharma, Inc. announced that it has received $2 million in funding	12.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kiromic BioPharma, Inc.

Aktien

A3D7BN

US4976342042

KRBP

Andere Sprachen

Filter